Description
Spegra Tablets: A Triple-Action Antiretroviral Therapy
Spegra Anti-HIV Tablets are a fixed-dose combination (FDC) therapy used for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents weighing at least $40\text{ kg}$. This once-daily regimen is highly valued for its potency, convenience, and effectiveness in controlling the virus.
The tablet combines three distinct antiretroviral agents:
| Component | Strength | Class of Drug | Primary Mechanism of Action |
| Dolutegravir (DTG) | $50\text{ mg}$ | Integrase Strand Transfer Inhibitor (INSTI) | Inhibits HIV Integrase, preventing the viral DNA from integrating into the host cell’s DNA. |
| Emtricitabine (FTC) | $200\text{ mg}$ | Nucleoside Reverse Transcriptase Inhibitor (NRTI) | Blocks the HIV Reverse Transcriptase enzyme, preventing the virus from replicating its genetic material. |
| Tenofovir Alafenamide (TAF) | $25\text{ mg}$ | Nucleotide Reverse Transcriptase Inhibitor (NtRTI) | A prodrug of Tenofovir that targets and inhibits the same reverse transcriptase enzyme as FTC. |
Clinical Use and Efficacy
This triple-action combination works synergistically to prevent the virus from multiplying and significantly reduce the viral load to undetectable levels, thereby strengthening the immune system (indicated by increased CD4 cell counts). Spegra is recommended for use in individuals who are either treatment-naïve (starting HIV therapy for the first time) or virologically suppressed (already on an effective regimen and switching for convenience or reduced toxicity).
Manufacturing, Safety, and Monitoring
Emcure Pharmaceuticals, a company well-known for its portfolio in HIV treatment, manufactures Spegra Anti-HIV Tablets. The film-coated tablets should be taken orally once daily, with or without food, under the guidance of a qualified healthcare provider.
| Common Side Effects | Important Safety Considerations | Monitoring Recommendations |
| Headache, fatigue, nausea, diarrhea, insomnia, gastrointestinal discomfort. | Lactic Acidosis and Severe Hepatomegaly: Rare but serious, requiring immediate medical attention if symptoms occur. | Kidney Function: Regular assessment of estimated creatinine clearance, urine glucose, and urine protein is essential due to the TAF component. |
| Severe Acute Exacerbation of Hepatitis B (HBV): Patients co-infected with HIV and HBV must be closely monitored for several months if treatment is discontinued. | Liver Function: Regular monitoring of liver enzymes, especially in patients with pre-existing liver conditions. | |
| Hypersensitivity Reactions: Discontinue immediately if signs of severe rash or organ dysfunction develop. | Immune Status: Periodic monitoring of CD4 cell counts and HIV viral load. | |
| Bone Mineral Density: TAF generally offers better bone safety than older formulations, but monitoring for bone density may be required in at-risk patients. | Metabolic Parameters: Monitoring of blood lipids and glucose levels as changes may occur during antiretroviral therapy. |
Availability & Purchase Information
Genetec Lifesciences makes Spegra Anti-HIV Tablets available. All medicines are sourced directly from Emcure or its authorized vendors.
Disclaimer
This site provides product information for informative purposes only. The product image belongs to its respective company. Genetec Lifesciences acts as a wholesaler and distributor, not a manufacturer. We source our medicines directly from the company or its authorized vendors.